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SUMMARY
Objectives: To assess similarities and differences
among currently available inhaled corticosteroids
(ICS) for treatment of asthma, with special
emphasis on factors that may affect the relative
safety of these medications.
Methods: PubMed was searched for relevant
reviews and original articles. Information from
these studies was synthesized and critically
assessed.
Results: Differences in corticosteroid formula-
tions and delivery systems can create variations in
therapeutic efficacy. Chemical properties of the
various corticosteroids may also affect their rela-
tive safety. Ciclesonide and beclomethasone
dipropionate are administered as prodrugs acti-
vated by enzymes present in the lungs but not the
oropharynx. Corticosteroid-specific adverse
effects in the oropharynx are thus avoided,
although formulation-specific effects may remain.
Other adverse effects require systemic availabil-
ity, either via the gastrointestinal tract or the
lung. Once they enter the systemic circulation,
all ICS are rapidly metabolized by the liver.
Oral bioavailability of ICS such as fluticasone,
ciclesonide and mometasone is minimal, as a
result of their essentially complete first-pass
metabolism in the liver. Ciclesonide also under-
goes extrahepatic metabolism that eliminates it
even more rapidly. Additionally, ciclesonide and
mometasone exhibit very high levels of binding
to serum proteins that reduces their ability to
stimulate glucocorticoid receptors outside the
lung.
Conclusions: Despite acting by similar mecha-
nisms, currently available ICS and their delivery
systems differ in ways that can potentially affect
both safety and therapeutic effectiveness for
individual patients.
Keywords: candidiasis, ciclesonide, dysphonia,
fluticasone, glucocorticoid, inhalers
INTRODUCTION
Inhaled corticosteroid therapy (ICS) revolutionized
the management of patients with asthma (1). For
the first time, it was possible to provide long-term
control of symptoms without the serious systemic
side-effects of oral corticosteroids. This was not,
however, the first use of inhalers in asthma
patients. Metered-dose inhalers had been intro-
duced in the 1950s for delivery of short-acting
b-agonist bronchodilators. This was followed
approximately a decade later by introduction of
dry-powder inhalers for delivery of sodium
cromoglycate. The first ICS was beclomethasone,
introduced in the early 1970s. Clinical trials quickly
demonstrated that patients previously maintained
on low-dose oral corticosteroids could be partially
or completely transferred to inhaled beclometha-
sone dipropionate with greater safety and little loss
of efficacy (2–4).
Today, ICS are the recommended first-line ther-
apy for persistent asthma of all severities and
patients of all ages (5) and are the most effective
asthma medications currently available. Limita-
tions and drawbacks remain, however. Whether
corticosteroids can inhibit the airway remodelling
characteristic of chronic asthma remains contro-
versial. Furthermore, an estimated 5–10% of all
asthma patients do not respond adequately to even
oral steroids (6–8). Additionally, although side-
effects of ICS are less frequent and less severe than
those of oral steroids, safety concerns remain.
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POTENTIAL ADVERSE EFFECTS
Effects in the oropharynx
Although use of inhaled as compared with oral
steroids dramatically reduces the incidence and
severity of systemic adverse effects, they raise
the possibility of local adverse effects specifically in
the oropharyngeal cavity. A significant fraction of
the delivered dose, perhaps as much as 90% (9),
may be deposited in the mouth and pharynx
without ever reaching the lungs.
The mechanisms underlying local adverse effects
of these oropharyngeally deposited corticosteroids
have not been extensively investigated, but appear
to include both immunologic and non-immuno-
logic actions. It is presumably suppression of local
immunity that leads to the increased risk of oral
candidiasis seen with use of ICS. The extent of the
risk is unclear, however, perhaps in part because
Candida colonization is often unassociated with
clinical symptoms (10), so studies reporting colo-
nization and those reporting clinical candidiasis are
not truly comparable. One study covering almost
26 000 patients age 65 and older who were using
ICS found a 3-year oral candidiasis incidence of 7%
(11), but whether this frequency would be observed
in patients of other ages remains uncertain. Fortu-
nately, the condition is usually easy to treat.
Dysphonia accompanying ICS use is common.
The true frequency remains unclear, however, with
reported incidences ranging from 5 to 50% (12).
The variations in reported incidence may reflect
both varying methods of ascertainment, often
patient questionnaires or incidental findings, and
varying definitions that may or may not differen-
tiate dysphonia from hoarseness of other aetiolo-
gies. Steroid-associated dysphonia has sometimes
been attributed to myopathy affecting the muscles
that control the vocal cords, but laryngoscopic
findings have been inconsistent (13). One study
found that switching from a metered dose inhaler
to a dry powder inhaler significantly reduced the
frequency of dysphonia, possibly because of dif-
ferences in position of the vocal cords during use of
the two devices (14).
Persistent cough and bronchospasm are
relatively uncommon side-effects of ICS use (13).
However, reflex cough during inhalation is quite
common. One study observed reflex cough in
34% of a mixed-age population using either
beclomethasone dipropionate or budesonide (15).
Both this study and another (16) found that use of a
large-volume spacer did not reduce the frequency
of cough. They likewise found no effect of differ-
ences in the medications tested. Lack of any
difference among ICS in the frequency of reflex
cough could point toward this being due to the
propellant or to irritant properties of other
components of the formulation.
In principle, steroid effects in the oropharyngeal
cavity can be avoided by administering the agent
as a prodrug that must be activated with an
enzyme present in the lung but not in the upper
respiratory tract. Ciclesonide is one such agent and
its prodrug status has often been cited as an
advantage. A pooled analysis found a lower inci-
dence of oropharyngeal adverse effects compared
with fluticasone, budesonide and beclomethasone
dipropionate as a group (13). It is difficult to tell
from the available data whether differences
between ciclesonide and beclomethasone dipropi-
onate, which is also administered as a prodrug,
were observed in this analysis. However, as other
studies have found little difference between
beclomethasone dipropionate and budesonide,
the prodrug concept remains open to question (13).
Suppression of the hypothalmic–pituitary–adrenal
(HPA) axis
Glucocorticoid secretion is governed by a negative
feedback loop in which activation of hypothalamic
glucocorticoid receptors results in reduced secre-
tion of corticotrophin-releasing hormone. This
leads to a decrease in release of adrenocorticotro-
phic hormone (ACTH) by the pituitary and conse-
quently of cortisol and other glucocorticoids by
the adrenal gland. As exogenous glucocorticoids
activate the hypothalamic glucocorticoid receptor,
they suppress production of endogenous gluco-
corticoids. Long-term, high-level suppression can
render endogenous production slow to recover, so
that sudden withdrawal of the exogenous agent
can result in acute adrenal insufficiency and adre-
nal crisis (17). There has also been concern about
possible adverse effects of lesser degrees of HPA
axis suppression, although this is controversial.
Even one-time administration of ICS has been
shown to produce measurable HPA axis
suppression. For example, a 500 lg dose of
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fluticasone administered via a dry-powder inhaler
produced a 29% reduction in nocturnal cortisol
secretion compared with the preceding night’s
values (18). Another study found that fluticasone
doses of 250, 500 and 1000 lg reduced plasma
cortisol area under the concentration–time curve
(AUC) for the first 20 h after dosing by 8%, 19%
and 28%, respectively, while a 800 lg dose of
budesonide reduced values by 16% (19). These
modest single-dose reductions are unlikely to be
clinically significant. However, a cross-sectional
study has found clearly abnormal (<5 lg ⁄ dL)
morning cortisol levels in 10 of 28 patients
receiving >660 lg of fluticasone for a year or more
(20). All of these patients also exhibited a low
response to ACTH stimulation. Furthermore, a
survey in the UK found that adrenal crisis had
been identified in 33 ICS users among the patients
of 709 responding physicians (21). Most of these
cases were children receiving fluticasone and
clinical practice recommendations have since been
changed to eliminate the doses at which adrenal
crisis was reported.
Other safety concerns
Skin thinning and ecchymoses. Use of ICS is associ-
ated with reduced synthesis of skin collagen (22),
which at higher doses leads to skin thinning and
ecchymoses (23) as well as to slow healing of skin
cuts and sores (24). Frequent bruising has been
documented in a number of large studies (24–27),
presumably reflecting capillary fragility as a result
of impaired collagen synthesis.
Decreased bone mineral density. Effects of ICS on
bone mineral density are controversial. Con-
founding factors include previous use of oral
corticosteroids and respiratory-related lifestyle
changes, such as limited exercise, that may them-
selves affect bone mineral density. However, even
studies designed to limit or avoid effects of oral
corticosteroid use may give conflicting results
(28–31), as do studies with biochemical markers of
bone formation and degradation (32–34). One
particularly well-designed study enrolled only
patients aged 20–40 with little or no previous oral
corticosteroid use. With major confounding factors
controlled, a negative relationship between bone
mineral density and cumulative lifetime dose of
ICS was observed (35). This is in accord with the
consensus of reviewers that long-term, high-dose
use of ICS may have significant effects on bone
mineral density (36–38), although a Cochrane
review disagrees (39). The Cochrane meta-analysis
of seven studies meeting inclusion criteria con-
cluded that there was no evidence of increased loss
of bone mineral density or of fracture risk and that
increases in osteocalcin levels (a measure of bone
mineral degradation) were seen only at doses
above those usually recommended.
Cataracts and glaucoma. Evidence for an association
between ICS use and development of posterior
subcapsular cataracts is likewise not completely
consistent. One small study found that cataract
incidence was associated only with prednisone use
(40). Two larger studies, however, have found an
association with dose and duration of ICS use (41,
42). A recent meta-analysis has reached the same
conclusion, finding that ICS increased cataract risk
significantly (43).
One large case–control study found an
increased risk of glaucoma or ocular hypertension
with high doses of ICS but not with ICS use in
general (44). Initiation of ICS use likewise showed
no effect on glaucoma incidence in a smaller pro-
spective study (45). Glaucoma thus does not seem
to be a general concern in patients receiving ICS,
although measurement of intraocular pressure
may be appropriate in select patients receiving
high doses.
Although safety concerns remain with ICS, these
do not offset the established beneficial profile of
these drugs. Most strikingly, one study has found
that prescribing an ICS to elderly patients being
discharged following an asthma-related hospital-
ization resulted, after adjustment for confounders,
in a 29% relative reduction in the risk of rehospi-
talization and a 39% reduction in the risk of death
during the following year (46). Nevertheless, the
National Heart, Lung, and Blood Institute’s Expert
Panel recommends use of the lowest possible ICS
dose that maintains asthma control, with consid-
eration being given to adding a long-acting b-ago-
nist to low- or medium-dose ICS therapy in
preference to further escalation of the ICS dose (5).
The panel also recommends calcium and vitamin D
supplements, and possibly bisphosphonates where
indicated.
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PHARMACOKINETICS AND
PHARMACODYNAMICS OF ICS
Oral and pulmonary bioavailability
Inhaler-delivered corticosteroids become systemi-
cally available by one of two routes. A large frac-
tion is deposited in the oropharyngeal cavity and is
then swallowed. Varying amounts will be absorbed
into the enterohepatic circulation and subjected to
first-pass metabolism in the liver. Oral bioavail-
ability (Table 1), which is defined as the fraction of
an oral dose that reaches the systemic circulation,
reflects both the fraction absorbed and the fraction
escaping first-pass metabolism. As an example, the
oral bioavailability of budesonide is approximately
11% (47). The oral bioavailability of beclometha-
sone, however, is approximately 41%, with 26% of
an inhaled dose becoming systemically available
via the gastrointestinal tract (48). By contrast, the
oral bioavailability of fluticasone and ciclesonide is
£1%, representing essentially complete first-pass
metabolism (49–51).
Essentially all drug that reaches the lungs and is
not removed by mucociliary clearance will even-
tually enter the systemic circulation. This means
that pulmonary bioavailability is determined by
inhaler design and the patient’s technique of usage,
along with size and physical properties of the
particle, but not by the chemical identity of the
drug. As typical examples, the pulmonary deposi-
tion, and hence bioavailability of ciclesonide using
a hydrofluoroalkane inhaler is 52% while that of
fluticasone is only 16% using the same inhalation
device (52). The difference probably reflects a dif-
ference in formulation (solution vs. suspension).
Particle size and composition also affect how dee-
ply the particle penetrates into the lung. Distal,
even deposition is therapeutically desirable but
does not ultimately influence systemic availability.
The absolute bioavailability of any ICS, defined
as oral plus pulmonary bioavailability, is always
less than 100%. Notably, the absolute bioavail-
ability of fluticasone is only about 16% (50). This
reflects a combination of incomplete absorption
from the gut and first-pass metabolism.
Pulmonary residence time
As ICS act therapeutically in the lung, it would
seem desirable for a drug to reside longer in the
lung before entering the systemic circulation.
Whether increased pulmonary residence time,
defined as the mean time between inhalation and
systemic absorption, actually increases the recep-
tor’s total exposure to active drug depends on the
mechanisms involved.
One factor affecting pulmonary residence time is
the rate at which inhaled particles dissolve. This
calls for a careful balance in drug design. A highly
soluble drug may dissolve quickly, giving a rapid
peak in drug concentration that then falls rapidly
as the drug enters the bloodstream. If the drug
dissolves too slowly, however, the particles may be
swept out of the lung by mucociliary clearance. The
rate of dissolution is affected by particle size, the
physical characteristics of the inhaled particle and
the chemical characteristics of the drug. The pos-
sibility that dissolution rate may be modified by
such formulations as coated particles and micro-
spheres is currently under investigation.
The other way in which pulmonary residence
time can be increased is by esterification of the
drug to a fatty acid. These esters are very highly
lipophilic and will typically be sequestered in the
cell membranes until the ester bond is hydrolysed
in the course of normal cell metabolism. How-
ever, these membrane-bound esters are not
available to activate pulmonary glucocorticoid
receptors. Thus, the net effect is to maintain a
pulmonary reserve of inactive drug. This ensures
relatively steady levels of active drug without
increasing total receptor exposure. Formation of
Table 1. Oral bioavailability of inhaled corticosteroids
Steroid Oral bioavailability
Beclomethasone dipropionate (48)
As unchanged compound <1%
As beclomethasone
17-monopropionate 41%
Budesonide 11–13% (47, 73)
Ciclesonide <1% (49)
Flunisolide 7% (77)
Fluticasone £1% (50, 78)
Mometasone No data availablea
Triamcinolone 23% (79)
aTotal systemic bioavailability has been reported as <1% after a
single inhaler-delivered dose and as 11% after multiple doses
(80).
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these fatty acid esters requires that the drug
have an unhindered hydroxyl at position 21. Such
a hydroxyl is present in budesonide (53),
triamcinolone (54) and the active metabolite of
ciclesonide, desisobutyryl-ciclesonide (55). Esters
of desisobutyryl-ciclesonide have been shown to
persist in the lung for more than 24 h (55).
Lung-specific activation
Beclomethasone dipropionate and ciclesonide are
administered as prodrugs that are activated in the
lung by esterase activity. Beclomethasone is
administered as the 17,21-dipropionate. Since a free
hydroxyl group at the 21 position is required for
activity, the prodrug is inactive until esterases in
the lung convert it to the active 17-monopropionate
and later to the less-active parent compound (48).
Ciclesonide is a 21-isobutyryl ester that is hydro-
lysed by the same enzymes to the active desiso-
butyryl-ciclesonide (56).
The relevant esterases are not present in the
oropharynx, so administration as a prodrug is
expected to improve oropharyngeal safety. These
enzymes are present elsewhere in the body, how-
ever, so any drug that escaped activation in the
lung will still be activated once it enters the sys-
temic circulation and can potentially contribute to
systemic adverse effects. The simultaneous pres-
ence of active and inactive forms complicates study
of the pharmacokinetics, though.
Lipophilicity
A highly lipophilic drug passes readily through the
cell membrane and thus reaches the glucocorticoid
receptor. This is equally true in the lung and in
extra-pulmonary tissues. Thus, both benefit and
risk are increased without any necessary alteration
in their ratio. An additional effect, however, is that
a larger fraction of a highly lipophilic drug will
leave the bloodstream and be temporarily seques-
tered in body tissues. In single-dose studies, this
will decrease the amount present in the blood-
stream. With chronic dosing, however, the drug
will accumulate in the tissues and an equilibrium
will be reached. Thus, once again, the effect will be
to dampen concentration fluctuations without
affecting the amount available on average to the
receptor.
The apparent volume of distribution is the vol-
ume that the total amount of drug in the body
would occupy if it were uniformly distributed at
the concentration in the blood. It is thus a measure
of the extent to which the drug leaves the blood-
stream and is sequestered in the tissues. Exchange
between blood and tissue, however, is an equilib-
rium process that reflects the amount of unbound
drug in each compartment as well as the ease with
which drug passes from one compartment to
another. A high level of binding to plasma proteins
tends to retain drug in the blood whereas high
liopophilicity is among the factors that contribute
to tissue entry and to binding and retention in the
tissues. Reflecting the balance of these two factors
as well as others, measured distribution volumes
range from approximately 180 L for budesonide to
almost 900 L for the active metabolite of ciclesonide
(52). Although apparent volume of distribution
influences drug half-life, the important factors
determining steady-state safety and efficacy are
lipophilicity and protein binding individually
rather than their combined effects on volume of
distribution.
Systemic clearance
Once a drug has entered the bloodstream, the rate
at which it is removed from the body becomes
important. Corticosteroids are metabolized pri-
marily by the liver and the clearance is typically
similar to or somewhat lower than the hepatic
blood flow rate (52). However, clearance of the
active metabolite of ciclesonide considerably
exceeds hepatic blood flow, indicating involvement
of extrahepatic sites of inactivation (57). As rapid
clearance decreases the AUC, such extrahepatic
inactivation is desirable and is likely to be a com-
mon feature in ICS introduced in the future.
An additional consideration is the extent to
which corticosteroids in the bloodstream are bound
to plasma proteins, predominantly albumin
(Table 2). Protein-bound corticosteroids do not
activate the glucocorticoid receptor. One might in
principle expect them to also be partially protected
from inactivation, but first-pass hepatic clearance
of ICS is so efficient that the effect is negligible in
practice. Thus, protein binding that renders the
drug unavailable during the period between
absorption from the lung and the time it reaches
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the liver is an almost unqualified advantage.
Reported protein binding for currently available
ICS ranges from 71% for triamcinolone to 99% for
ciclesonide and its active metabolite (52). There has
been a general trend toward increased protein
binding by newer ICS, and it is likely that 97–99%
binding will remain standard for any that may be
introduced in the future.
Potency
Potency (Table 3) is affinity for the receptor, that is,
the fraction of receptor bound and activated at a
given drug concentration. As the same receptor is
responsible for both therapeutic and adverse
effects, high potency would not in itself alter the
risk ⁄ benefit ratio. However, whereas the thera-
peutic effect of most ICS appears to plateau at
doses only modestly above those currently recom-
mended (7) – for example, evidence indicates that
there is no therapeutic advantage to increasing the
budesonide dosage above 1600 lg ⁄ day (58) – this
appears to be less true for the newer, more potent
corticosteroids fluticasone (59) and ciclesonide (60).
The same may be true for mometasone (61), where
one study in patients with severe, persistent
asthma found that doses ranging up to 1600
lg ⁄ day (four times the usual dose) allowed 76% of
those patients to completely eliminate usage of oral
prednisone (62). Such dose escalation becomes
particularly attractive when high potency is com-
bined with low oral bioavailability.
METHODS OF DELIVERY TO THE LUNG
Since the therapeutic target of ICS is the lung, a
method for delivery to that site is required. The
ideal goal would be to deliver drug specifically to
the lung and nowhere else, but unfortunately
none of the current methods approach that goal.
Nevertheless, there are significant differences
among the currently available delivery methods.
There are currently three methods by which
corticosteroids can be delivered to the lung:
metered dose inhalers (MDIs), dry powder inhalers
(DPIs) and nebulizers. MDIs have the drug either
dissolved or suspended in a liquefied, pressurized
propellant. Pressing the actuator button briefly
releases the pressure, converting a measured
amount of propellant into an aerosol delivered
from the orifice. Older MDIs used chlorofluoro-
carbons (CFCs) as the propellant, but following
adoption of the Montreal Protocol on Substances
That Deplete the Ozone Layer those were gradually
phased out in favour of the hydrofluoroalkanes
(HFAs) used today. MDIs require the patient to
inspire as the button is pressed, a technique that
many find difficult to master. Indeed, fully three-
quarters of patients (63) do not use the correct
technique while more than 40% of nurses and
faculty at an academic medical center perform at
least four of the seven steps incorrectly (64). This is
one factor that has led to adoption of large-volume
spacers or holding chambers for use with MDIs,
since these devices retain the drug within the
chamber until the patient breaths in. They also
facilitate anatomically correct placement of the
device outlet and reduce the shock of cold pro-
pellant hitting the back of the throat that sometimes
causes patients to halt inspiration. These spacers
significantly increase the overall bulk of the
device, however, and attention to technique is still
required.
With DPIs, it is the patient’s own inspiration that
provides the energy for drug delivery. That breath
draws air through the drug, formulated as a dry
powder. The drug is then entrained in the inspired
Table 2. Protein binding of inhaled corticosteroids











Table 3. Rank order of inhaled corticosteroid potency
(highest to lowest)
Mometasone (82)
Fluticasone (82–84)  Ciclesonide (83)
Budesonide (84)  Triamcinolone (84)
Flunisolide (84)
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air, with screens or spinning surfaces used to break
up the aggregates that micronized particles would
otherwise form. DPIs do not require hand-breath
coordination, but do require fairly strong inspira-
tory force (exactly how strong varies with the
specific device). However, even asthma patients
with reduced ventilatory volume can usually
generate adequate inspiratory force, since the
reduced volume primarily affects duration rather
than force of inhalation (65).
Nebulizers convert a liquid solution or suspen-
sion into an aerosol using either a jet of compressed
air or ultrasonic energy. The aerosol plume is then
delivered to the patient through either a face mask
or a mouthpiece. These devices make minimal
demands on patient technique. Even with modern
advances, however, they remain relatively bulky
and are therefore typically prescribed only for
patients unable to use either MDIs or DPIs.
A systematic review has found that nebulizers
appear at least as effective for ICS delivery as MDIs
with large-volume spacers (66).
Delivered particle size is an important consid-
eration in choice of an inhaler. Particles should
ideally be between 1 and 5 lm in diameter, because
larger particles are likely to be deposited in the
oropharynx while very small particles will either
be deposited in the upper airways or, if drawn into
the lower airways, will be exhaled (67). Since
replacement of CFCs by HFAs as the propellant
required MDI redesign, many manufacturers uti-
lized the opportunity to optimize design in other
respects as well. Thus, while an older CFC-driven
MDI deposited only 4–7% of beclomethasone
dipropionate leaving the device into the lungs, the
newer HFA-driven inhaler deposits 55–60% (9).
Older studies comparing DPIs with CFC-driven
MDIs are therefore no longer meaningful. The
HFA-driven fluticasone inhaler, however, was
deliberately designed to have the same particle size
distribution and lung deposition as the CFC-driven
device in order to maintain dosage comparability.
This inhaler already had a relatively fine particle
size, however, with the proportion of particles
<5 lm in diameter being considerably higher than
that seen for the same drug delivered by the
Diskhaler DPI (68).
Particle sizes delivered by DPIs also differ
between devices. Because of the large number of
different designs, however, generalizations are
difficult and only a limited number of possible
comparisons have been addressed. One review has
concluded that the Turbuhaler delivers twice as
much of the administered drug to the lung as does
the Diskus (69), but the studies cited are compli-
cated by delivery of different drugs from the two
devices. Clinical results may be of more interest,
especially when the same drug is being adminis-
tered. One such study found that patients receiving
beclomethasone dipropionate via the Diskhaler
(similar but not identical to the Diskus) were more
likely to have used little or no short-acting b-ago-
nist than were those receiving the same drug via
the Rotohaler (70). A comparison of budesonide
delivered by Airmax or Turbuhaler found that
patients using the Airmax demonstrated a non-
signficant trend toward greater improvement in
airway hyper-responsiveness but with no differ-
ence in forced expiratory volume in 1 s, peak
expiratory flow or symptoms (71). Turning to
nebulizers, Dahlström et al. (72) found no differ-
ence in lung deposition of budesonide as a function
of nominal dose for three different jet nebulizers
[the Inhalierboy, the LC Jet Plus (Pari Gmbh,
Starnberg, Germany) and the MA-2 (Clinova
Medical AB, Malmo, Sweden)], although a larger
fraction of the dose actually delivered by the
Inhalierboy was deposited in the oropharynx.
Although early studies reported that the
Turbuhaler delivered twice as much budesonide to
the lungs as did a MDI (73), and that this was
reflected in patients prescribed a Turbuhaler get-
ting the same or greater benefit with half the dose
(65), these studies were all done with the CFC-
driven MDI. Current evidence indicates no clinical
difference among the various devices (74). Specifi-
cally, no differences in effectiveness or safety were
seen in relatively short-term randomized con-
trolled trials, although oropharyngeal adverse
effects were not examined. However, such studies
typically require all enrolled patients to demon-
strate an ability to use the device correctly and
otherwise gloss over factors that may be important
for individual patients. Thus, choosing the correct
delivery method for a specific patient calls for
knowledge of both the device and the patient.
Aside from patient ability and willingness to use a
given device, patient preference may also be a
factor, as may the availability of a given delivery
device for the drug of choice.
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FUTURE DIRECTIONS
Only a limited number of pathways toward safer
and more effective ICS are available. Because ther-
apeutic and adverse effects are exerted through the
same receptor, greater selectivity through structural
modification is not an option. Recently introduced
agents exhibit near-maximum first-pass metabolism
and protein binding, so further improvement in
those respects is likewise not an option. Further-
more, one of those recently introduced drugs,
ciclesonide, is a prodrug that remains inactive in the
oropharyngeal cavity and that also exhibits
relatively prolonged pulmonary residence time.
Nevertheless, approaches to improved ICS are
still available. One is so-called ‘soft drugs’ that are
rapidly inactivated on leaving the desired site of
action. As ciclesonide’s clearance exceeds hepatic
blood flow, it could be considered a soft drug.
There is no reason, however, to believe that
ciclesonide’s rate of extrahepatic metabolism is
maximal, so room for improvement presumably
exists. Bodor & Buchwald (75) review approaches
to development of soft corticosteroids and discuss
several that are currently in development for
asthma or are approved for other indications.
These are predominately esters with inactive
hydrolytic metabolites, with prolonged pulmonary
residence time being the primary approach to
achieve the desired pulmonary selectivity. A more
intuitively attractive approach would be to look for
drugs metabolized by enzymes present in the
bloodstream but not in the lung. This appears to be
true of glucocorticoid c-lactones metabolized by
paraoxonase, but reports suggest that such com-
pounds may have proven unsatisfactory.
It has also been suggested that compounds
might be developed that selectively activate the
glucocorticoid receptor so as to transrepress pro-
inflammatory transcription factors such as NF-jB
and AP-1 without promoting transcription of genes
with glucocorticoid response elements (76).
Attempts to develop such compounds have had
limited success, however, and it is not even clear
that such selective activation is possible.
CONCLUSION
Although ICS remain the accepted initial therapy
for persistent asthma, safety concerns persist.
These concerns are especially significant when it
becomes desirable to escalate the dose beyond
those usually recommended. Cataracts and loss of
bone mineral density may be especially significant.
Suppression of the HPA axis is often seen but
becomes clinically significant, at least in adults,
only at extremely high doses. Recent developments
have eased some of these concerns, as newer ICS
have essentially zero oral bioavailability and exhi-
bit 98–99% binding to serum proteins. Some are
also prodrugs that remain inactive in the orophar-
ynx and therefore do not produce local adverse
effects. Successful efforts to improve delivery
devices are also ongoing. With further research,
safer or even virtually risk-free ICS may be antici-
pated.
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